Can Alström syndrome cause cardiomyopathy in infancy?

Yes, Alström syndrome can cause cardiomyopathy in infancy, and in some babies it is one of the earliest and most serious signs of the condition. For families, this is one of the most frightening parts of the syndrome because it can present as heart failure in very young babies, sometimes before anyone understands the bigger genetic picture.

The short answer is that infantile cardiomyopathy is a recognised and important feature of Alström syndrome. Research reviews and case reports describe severe dilated cardiomyopathy in the first months of life, often with heart failure symptoms. Some babies improve significantly over time, but that does not mean the heart can be forgotten. Ongoing follow-up still matters because later cardiac problems can return in a different form.

A 2024 case report and literature review in Frontiers in Pediatrics adds an especially useful example. The paper described a 4-month-old baby girl referred for a systolic murmur after respiratory distress. Evaluation showed dilated cardiomyopathy with severe systolic dysfunction of the left ventricle, elevated cardiac markers, and eventually the wider pattern that led to suspicion of Alström syndrome. Later, the child developed vertical nystagmus and was found to have cone-rod dystrophy, and genetic testing confirmed a homozygous ALMS1 variant.

That case matters because it shows how infantile cardiomyopathy can be one of the first major signs and how diagnosis may initially go in a different direction, in this case suspected viral myocarditis, before the broader syndrome becomes clear.

Cardiac involvement is common in Alström syndrome. The 2024 paper notes reported incidence figures for dilated cardiomyopathy ranging between 30 percent and 60 percent at different life periods. It also states that most patients with early cardiac disease present with heart failure caused by severe dilated cardiomyopathy in the first months of life.

The paper also cites prior work indicating that around 40 percent of neonates may experience heart failure between 4 weeks and 3 months of age. Even when exact figures vary between studies, the message is clear: early cardiomyopathy is not a rare side issue in Alström syndrome. It is one of the major reasons the condition can become life threatening in infancy.

In real life, cardiomyopathy in a baby may present through fast breathing, feeding difficulty, sweating with feeds, poor weight gain in some cases, lethargy, persistent respiratory distress, wheezing, or a newly detected murmur. Some of these symptoms can be mistaken for infection or lung disease first, which is one reason diagnosis may be delayed.

In the 2024 case report, the infant first came to attention after respiratory distress and was initially treated in the context of presumed infection, while later evaluation showed the much more serious cardiac picture. That pattern matters for parents because it shows how heart disease may not always announce itself in an obvious textbook way.

The exact pathophysiology of dilated cardiomyopathy in Alström syndrome is still not fully understood. The 2024 paper links ALMS1 dysfunction to primary cilia and centrosome biology and also notes recent work suggesting TGF-beta pathway involvement, which may contribute to the fibrosis seen more broadly in the disease. The widespread expression of ALMS1 across tissues helps explain why the heart is one of the organs affected.

The paper also mentions that a more extreme form called mitogenic cardiomyopathy has been described in rare cases and may be connected to disrupted post-natal cardiomyocyte cell cycle arrest. For families, the practical takeaway is not memorising the molecular pathway. It is understanding that this is a real disease mechanism, not a random unrelated heart problem.

Yes, they can, and this is one of the most important things families need to hear alongside the seriousness. The 2024 case report described gradual improvement in the child’s left ventricular function over the following months, with cardiac markers returning to normal. The paper also notes that survivors of infantile dilated cardiomyopathy often recover cardiac function within the first years of life, usually by around age 3, and may maintain a normal or low-normal level of function for several years.

This matters because it gives families a more accurate picture. Infantile cardiomyopathy in Alström syndrome is serious and can be life threatening, but improvement is possible. The story is not automatically hopeless.

Even when heart function improves, the cardiac story may not be over. Reviews cited in the paper note that congestive heart failure can recur later in adolescence or young adulthood, sometimes in the form of restrictive cardiomyopathy related to diffuse interstitial fibrosis. This means that early recovery does not remove the need for lifelong follow-up.

For parents, this changes the framing. The goal is not only surviving the infantile phase. It is building long-term surveillance around a heart that may remain vulnerable over time.

The presence of early cardiomyopathy is one of the reasons Alström syndrome may be diagnosed more quickly in some children. In the earlier diagnosis-pathway report, visual impairment together with cardiomyopathy tended to lead to faster diagnosis than visual impairment alone. That makes sense because a dramatic multi-organ pattern is harder to dismiss.

Still, as the 2024 case report shows, the first explanation is not always the right one. Viral myocarditis was initially suspected before the wider syndrome picture emerged. That is why cardiomyopathy should always be interpreted in context when other red flags are present.

If a baby with suspected or confirmed Alström syndrome has heart involvement, it helps to ask direct questions. Is this dilated cardiomyopathy? How severe is the systolic dysfunction? What medications are being used? What does the current echocardiogram show? How often will the heart be rechecked? If function improves, what long-term follow-up is still needed?

Parents should also ask whether other parts of the syndrome are being assessed at the same time, especially vision, hearing, metabolic markers, liver function, and kidney function, because the heart is often not the only organ involved.